share_log
Hi,
moomoo ID:0
Log Out
English
Back
  • English
  • 中文繁体
  • 中文简体

Talaris Therapeutics (NASDAQ:TALS) Trading 7% Higher

Defense World ·  11/11/2022 15:21

Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating)'s share price rose 7% during trading on Thursday . The stock traded as high as $1.57 and last traded at $1.53. Approximately 200,841 shares were traded during mid-day trading, an increase of 50% from the average daily volume of 133,473 shares. The stock had previously closed at $1.43.

Wall Street Analysts Forecast Growth

TALS has been the subject of several recent research reports. Evercore ISI lifted their target price on shares of Talaris Therapeutics to $20.00 in a report on Monday, August 15th. HC Wainwright started coverage on shares of Talaris Therapeutics in a report on Thursday, October 20th. They issued a "buy" rating and a $18.00 price objective for the company. Finally, Morgan Stanley decreased their price objective on shares of Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Friday, September 9th.

Get Talaris Therapeutics alerts:

Talaris Therapeutics Stock Performance

The stock has a market capitalization of $63.80 million, a PE ratio of -1.01 and a beta of 1.94. The stock's 50 day moving average is $2.53 and its two-hundred day moving average is $4.62.

Talaris Therapeutics (NASDAQ:TALS – Get Rating) last announced its earnings results on Monday, August 15th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02. Equities research analysts expect that Talaris Therapeutics, Inc. will post -1.85 EPS for the current fiscal year.

Insider Activity at Talaris Therapeutics

In other news, insider Suzanne Ildstad sold 525,000 shares of the company's stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $2.80, for a total value of $1,470,000.00. Following the completion of the sale, the insider now directly owns 3,081,446 shares in the company, valued at $8,628,048.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 16.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TALS. Bank of Montreal Can increased its stake in Talaris Therapeutics by 1,388.6% during the third quarter. Bank of Montreal Can now owns 334,061 shares of the company's stock worth $1,193,000 after acquiring an additional 311,619 shares during the last quarter. State Street Corp increased its position in shares of Talaris Therapeutics by 40.6% during the 1st quarter. State Street Corp now owns 261,465 shares of the company's stock worth $2,573,000 after purchasing an additional 75,463 shares during the last quarter. BlackRock Inc. raised its holdings in Talaris Therapeutics by 1.6% in the 1st quarter. BlackRock Inc. now owns 2,433,914 shares of the company's stock valued at $23,950,000 after buying an additional 38,449 shares during the period. Nicholas Investment Partners LP acquired a new position in Talaris Therapeutics in the first quarter valued at about $221,000. Finally, Rhumbline Advisers lifted its position in Talaris Therapeutics by 112.3% in the second quarter. Rhumbline Advisers now owns 31,713 shares of the company's stock valued at $143,000 after buying an additional 16,772 shares during the last quarter. 67.99% of the stock is currently owned by institutional investors and hedge funds.

About Talaris Therapeutics

(Get Rating)

Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.

Featured Articles

  • Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
  • Six Flags is a Ride You Don't Want to Get Stuck On
  • Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
  • Hanesbrands May be Signaling a Bad Week for Retail Stocks
  • Coupang Stock And Why You Should Care
  • This Is No Time To Buy D.R. Horton Stock

Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.